Two-year survival with nivolumab in previously treated, advanced non-small cell lung cancer: A pooled analysis of real-world patients from France, Germany and Canada.

Martin Sebastian,Clarisse Audigier Valette,Charles A. Butts,Didier Debieuvre,A. Dixmier,Andreas Groschel,Sylvia Gütz,Rosalyn A. Juergens,Catherine Labbé,Denis Moro-Sibilot,Maurice Pérol,Christian Schumann,Ariadna Juarez-Garcia,Khalid Lakhdari,John R. Penrod,Filippa Pettersson,Dorothee Reynaud,D Waldenberger,Victoria Allan,Fabrice Barlesi

Two-year survival with nivolumab in previously treated, advanced non-small cell lung cancer: A pooled analysis of real-world patients from France, Germany and Canada.

2020

e21714Background: Data from clinical studies demonstrate a long-term survival benefit of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC) patients with overall survival (...

Keywords:

pooled analysis
Nivolumab
Lung cancer
Oncology
non small cell
Internal medicine
Medicine
previously treated
Pathology

Correction
Source
Cite
Save

References

Citations